Search Results - "Fisher, G V"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    LUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation

    LUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation by Gelmon, K.A., Walker, G.P., Fisher, G.V., McCutcheon, S.C.

    Published in Annals of oncology (01-10-2018)
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers

    Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers by Yates, R A, Dowsett, M, Fisher, G V, Selen, A, Wyld, P J

    Published in British journal of cancer (01-02-1996)
    “…Two multiple-dose studies were conducted in healthy post-menopausal female volunteers to investigate the pharmacokinetics and effects on endocrinology of…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Arimidex (ZD1033) : a selective, potent inhibitor of aromatase in post-menopausal female volunteers

    Arimidex (ZD1033) : a selective, potent inhibitor of aromatase in post-menopausal female volunteers by YATES, R. A, DOWSETT, M, FISHER, G. V, SELEN, A, WYLD, P. J

    Published in British journal of cancer (1996)
    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    367TiPLUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation

    367TiPLUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation by Gelmon, K A, Walker, G P, Fisher, G V, McCutcheon, S C

    Published in Annals of oncology (01-10-2018)
    Get full text
    Journal Article
    Save to List
    Saved in:
  5. 5
    Abstract OT3-04-04: LUCY: A phase IIIb, single-arm, open-label multicenter study of olaparib in patients with HER2-negative metastatic breast cancer and a germline BRCA1/2 mutation

    Abstract OT3-04-04: LUCY: A phase IIIb, single-arm, open-label multicenter study of olaparib in patients with HER2-negative metastatic breast cancer and a germline BRCA1/2 mutation by Gelmon, K, Walker, GP, Fisher, GV

    Published in Cancer research (Chicago, Ill.) (15-02-2018)
    “…Abstract Background Olaparib (Lynparza) is a PARP inhibitor with activity in patients with advanced cancers who have a germline BRCA1 and/or BRCA2 (gBRCA)…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  6. 6
    An introduction to chaos theory and some haematological applications

    An introduction to chaos theory and some haematological applications by Fisher, G. V.

    Published in Comparative Haematology International (01-03-1993)
    Get full text
    Journal Article
    Save to List
    Saved in:
  7. 7
    Rat lymphocyte subset analysis using the technicon H1

    Rat lymphocyte subset analysis using the technicon H1 by Fisher, G. V.

    Published in Comparative Haematology International (01-12-1993)
    Get full text
    Journal Article
    Save to List
    Saved in:
  8. 8
    The validation and application of the technicon H1 for the complete automated evaluation of laboratory animal haematology

    The validation and application of the technicon H1 for the complete automated evaluation of laboratory animal haematology by Davies, D. T., Fisher, G. V.

    Published in Comparative Haematology International (01-05-1991)
    Get full text
    Journal Article
    Save to List
    Saved in:
  9. 9
    Semiconductor-Tuned High-T Superconductor Filters for Ultrasensitive RF Receivers (SURF): Technology development and evaluation

    Semiconductor-Tuned High-T Superconductor Filters for Ultrasensitive RF Receivers (SURF): Technology development and evaluation by Cerny, C. L. A., Fisher, V. G., McCartney, J. T., Ovenshire, D. A.

    “…The DARPA/STO Semiconductor-Tuned High Temperature Superconductor Filters for Ultrasensitive RF Receivers (SURF) Program was initiated for the purpose of…”
    Get full text
    Conference Proceeding
    Save to List
    Saved in:

Search Tools: